Oncolytics Biotech Inc. (ONCY)

[ash111]

ONCY DD: a remarkable number of ongoing clinical trials considering its low share price.many P2 Clinical Trials,and even a P3Q1 results:

Oncolytics Biotech is conducting clinical trials in multiple indications with the objective of developing REOLYSIN® as a human cancer therapeutic. The current clinical program comprises human trials using REOLYSIN® both alone and in combination with chemotherapy, delivered via local and/or intravenous administration. In May 2010, the Company commenced enrollment for its first Phase III clinical trial, REO 018, investigating the intravenous administration of REOLYSIN® in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers.

http://www.oncolyticsbiotech.com/clinical-trials/default.aspx

Primed numbers/Solid Balance Sheet: Total assets almost doubled in 3 months!! 31,444,945 vs 17,193,190

Total current liabilities only 4,274,515

Assets/Debt ratio SUPER SOLID =4+

Cash and cash equivalents, end of period (increased by $8m) 28,578,023 vs 20,155,907

Market value simply a joke.

http://www.oncolyticsbiotech.com/files/Oncolytics_1st-Quarter_2015_web_v001_i9e5xh.pdf

On the ratings front, Oncolyticshas been the subject of a number of recent research reports. In a report issued on June 8, Canaccord Genuity analyst Neil Maruoka maintained a Buy rating on ONCY, with a price target of $2.50, which implies an upside of 363.0% from current levels. Separately, on March 18, Needham’s Chad Messer reiterated a Buy rating on the stock and has a price target of $1.50.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Neil Maruoka and Chad Messer have a total average return of 8.3% and 2.9% respectively. Maruoka has a success rate of 50.0% and is ranked #1117 out of 3689 analysts, while Messer has a success rate of 38.2% and is ranked #1519.

Oncolytics Biotech Inc is a development stage biopharmaceutical company. It is engaged in the discovery and development of pharmaceutical products for the treatment of cancer".

http://www.smarteranalyst.com/2015/07/06/company-update-nasdaqoncy-oncolytics-biotech-inc-usa-collaborators-present-final-data-from-reo-017-clinical-study-in-pancreatic-cancer/